

REMARKS

Applicants provisionally elect with traverse Group I, drawn to bis-piperidinyl compounds such as those set forth in claim 11, classified in class 546 subclass 193. Claims reading on this election are claims 1-12 and 18 where p and q are each 1.

An amended set of claims in which p is 1 and q is 1 is included with this response. As amended the application now contains claims 1-5, 7-12, 16, and 18. Claims 6, 13-15, and 17 have been canceled.

It is respectfully submitted that the present application is in condition for examination and allowance, and a Notice of Allowance is earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

Bonnie L. Deppenbrock
Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 11/20/08

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988